arrow_backToday
Archive
Cardiology — 414 items, newest first. Nothing is deleted.
Friday, 11 September 2026
Polyvascular Atherosclerotic Disease: A Narrative Review of the Role of Systematic Bedside Vascular Examination
No original data or effect estimates are reported; the review argues that abnormal bedside findings should prompt selective ABI, duplex, CTA, MRA or cardiac testing rather than indiscriminate imaging.
Cardiology · Cureus · 18h
ARPA-H launches $63M effort to build FDA-authorized AI agents for heart failure care
Autonomous AI agents for heart failure could soon reach your clinic with FDA oversight, so watch how these tools are validated before adoption.
Cardiology · Fierce Healthcare · 21h
Tricuspid Stenosis Due to Cardiac Sarcoma
Echocardiography showed a large right atrial mass obstructing tricuspid inflow plus significant pericardial effusion; resection confirmed biphasic synovial sarcoma. Postoperatively he developed atrial flutter with left ventricular dysfunction needing cardioversion.
Cardiology · Cureus · 22h
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
An AI ECG reader cleared to flag occult coronary occlusion could catch NSTEMI and posterior MI patterns that clinicians and standard algorithms miss.
Cardiology · STAT News — Health Tech · 24h
Thursday, 10 September 2026
Right Coronary Artery Thrombosis Causing ST-Elevation Myocardial Infarction After a Coronary Artery Disease Reporting and Data System Score of 0, With Disseminated Intravascular Coagulation During Idiopathic Acute Pancreatitis: A Case Report
A 99% thrombotic subtotal occlusion of the mid-right coronary artery caused inferior STEMI; coronary CT angiography five months earlier had shown an Agatston score of 0 and CAD-RADS 0.
Cardiology · Cureus · 2d
Temporary Left Ventricular Unloading With Impella as a Bridge to Emergency Surgery for Acute Mitral Bioprosthetic Failure
Cardiac index and mixed venous oxygen saturation rose and oxygenation held on less inspired oxygen; mean pulmonary artery pressure stayed around 40 mmHg and did not keep climbing
Cardiology · Cureus · 2d
Wednesday, 9 September 2026
STAT+: ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure
AI-guided heart failure therapy could soon be FDA-authorized, potentially changing how you titrate medications and monitor patients.
Cardiology · STAT News — Health Tech · 3d
Abbott garners FDA nod for its TactiFlex catheter to treat AFib
A new ablation catheter option for AFib may improve procedural flexibility and outcomes in your electrophysiology cases.
Cardiology · Fierce Biotech · 3d
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial.
Mitiperstat (pooled doses) did not improve KCCQ-TSS (placebo-corrected difference -1.4 points, 95% CI -3.9 to 1.2; P=0.29) or 6MWD (3.8 m, 95% CI -3.1 to 10.8; P=0.28) or any secondary endpoint.
Cardiology · Nature Medicine · 3d
Tuesday, 1 September 2026
Dapagliflozin and Risk of Perioperative Acute Kidney Injury in Cardiac Surgery
Perioperative AKI after cardiac surgery is common; this trial tests whether continuing SGLT2 inhibitors changes that risk, informing your pre-op medication decisions.
Cardiology · JAMA · 11d
SGLT2 Inhibitors for Prevention of AKI
Starting dapagliflozin the day before elective cardiac surgery may cut postoperative AKI—consider timing and renal risk in your surgical patients.
Cardiology · JAMA · 11d
Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery Research Summary
If dapagliflozin cuts post-op AKI, you can start it pre-surgery to protect kidneys in high-risk cardiac patients.
Cardiology · JAMA · 11d
Boston Scientific halts sales of angiographic catheters amid 2 serious injuries
Check your stock of Imager II catheters; tip defect may cause serious injury—stop use and follow recall instructions.
Cardiology · Fierce Biotech · 11d
Monday, 31 August 2026
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
For cardiologists managing ATTR-CM, this suggests RNAi may still benefit patients on tafamidis despite the Wainua failure—watch for confirmatory data.
Cardiology · Fierce Biotech · 12d
ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial
Oral relaxin agonist improved cardiac function in chronic heart failure—watch for a potential new add-on beyond standard therapy.
Cardiology · Fierce Biotech · 12d
Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark.
Primary endpoint occurred in 139/499 (28%) intervention vs 128/501 (26%) control (HR 1.10, 95% CI 0.86-1.39; p=0.45). No benefit.
Cardiology · Lancet · 13d
Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.
Primary composite event occurred in 2/280 (0.7%) thrombolysis vs 19/278 (6.8%) standard care (RR 0.10, 95% CI 0.02-0.44, P<0.001), driven by reduced cardiorespiratory decompensation. Major bleeding 1.4% vs 2.2% (P=0.54).
Cardiology · NEJM · 13d
Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.
In HFrEF, ARNI+SGLT2i+sMRA reduced SBP by -9.2 (-10.6 to -7.8) mmHg, eGFR by -6.8 (-7.9 to -5.4) ml/min/m2, increased potassium by +0.30 (0.25-0.35) mmol/l. In HFmrEF/HFpEF, SGLT2i+sMRA reduced SBP -5.9 (-7.3 to -4.6) mmHg, eGFR -7.7 (-8.9 to -6.4), potassium +0.34 (0.29-0.38).
Cardiology · Nature Medicine · 13d
Page 1